RxDoctor Payments Data

Gretchen Gignac, MD

Medical Oncology · Boston, MANPI 1821288960

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in MA, where the typical reported total is $2,567.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$101,666in research payments, 2019–2025

Across 19 payments — averaging $5350.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$82K
  • Seagen Inc.$18K
  • Merck$1K
  • Amgen$983

How this compares

$0 in reported general payments places this provider in the 10th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$42,461
Medicare patients
134
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide94$988,712
OrgovyxRelugolix294$765,262
ErleadaApalutamide23$341,878
XtandiEnzalutamide32$329,287
Abiraterone Acetate57$20,778
Bicalutamide53$672
Tamsulosin Hcl20$193
Prednisone60$193
Dexamethasone16$144
Ondansetron Hcl12$63

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →